363 related articles for article (PubMed ID: 34123366)
21. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.
Bleecker E; Blaiss M; Jacob-Nara J; Huynh L; Guo T; Ye M; Stanford RH; Wang Z; Soler X; Nag A; Nair R; Borsos K
Allergy Asthma Proc; 2024 May; ():. PubMed ID: 38760161
[TBL] [Abstract][Full Text] [Related]
23. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system.
Sousa J; Taborda-Barata L; Monteiro C
Expert Opin Drug Saf; 2020 Jan; 19(1):99-106. PubMed ID: 31661986
[No Abstract] [Full Text] [Related]
24. Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
Park S; Park SH; Byun YJ; Choi SA
PLoS One; 2022; 17(7):e0270906. PubMed ID: 35895603
[TBL] [Abstract][Full Text] [Related]
25. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
26. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
Domingo C
Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
[TBL] [Abstract][Full Text] [Related]
27. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Stack TJ; Kim S; Lamb MM; Mohammad I; Zeatoun A; Lopez E; Klatt-Cromwell C; Thorp BD; Ebert CS; Senior BA; Kimple AJ; Alicea D
ORL J Otorhinolaryngol Relat Spec; 2023; 85(6):329-339. PubMed ID: 37963438
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies in severe asthma: is it worth it?
Calzetta L; Matera MG; Rogliani P
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):517-520. PubMed ID: 31104515
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642
[TBL] [Abstract][Full Text] [Related]
30. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.
Matera MG; Calzetta L; Rogliani P; Cazzola M
Respir Med; 2019 Jul; 153():3-13. PubMed ID: 31136930
[TBL] [Abstract][Full Text] [Related]
32. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
[TBL] [Abstract][Full Text] [Related]
33. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.
Chiarella SE
Allergy Asthma Proc; 2019 Nov; 40(6):485-489. PubMed ID: 31690400
[TBL] [Abstract][Full Text] [Related]
34. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review.
Matucci A; Vultaggio A; Danesi R
Respir Res; 2018 Aug; 19(1):154. PubMed ID: 30115042
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.
AlShareef S; McDonald CF; Lee J
J Asthma Allergy; 2022; 15():209-217. PubMed ID: 35210787
[TBL] [Abstract][Full Text] [Related]
36. Biologic therapy practices in severe asthma; outcomes from the UK Severe Asthma Registry and survey of specialist opinion.
Mansur AH; Gonem S; Brown T; Burhan H; Chaudhuri R; Dodd JW; Pantin T; Gore R; Jackson D; Menzies-Gow A; Patel M; Pavord I; Pfeffer P; Siddiqui S; Busby J; Heaney LG;
Clin Exp Allergy; 2022 Sep; ():. PubMed ID: 36057784
[TBL] [Abstract][Full Text] [Related]
37. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.
Lin RY; Rodriguez-Baez G; Bhargave GA
Ann Allergy Asthma Immunol; 2009 Nov; 103(5):442-5. PubMed ID: 19927545
[TBL] [Abstract][Full Text] [Related]
38. Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management.
Sitek A; Chiarella SE; Pongdee T
Front Allergy; 2023; 4():1219735. PubMed ID: 37637139
[TBL] [Abstract][Full Text] [Related]
39. Safety of biological therapy in elderly patients with severe asthma.
Mir-Ihara P; Narváez-Fernández E; Domínguez-Ortega J; Entrala A; Barranco P; Luna-Porta JA; Romero D; Villamañán E; Losantos-García I; Quirce S
J Asthma; 2022 Nov; 59(11):2218-2222. PubMed ID: 34889165
[TBL] [Abstract][Full Text] [Related]
40. Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps.
Mandl HK; Miller JE; Beswick DM
Otolaryngol Clin North Am; 2024 Apr; 57(2):225-242. PubMed ID: 37684154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
